Clinical Trials Browser

Phase 1/2 × Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all

NCT01311713 2024-01-30

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Phase 1/2 Terminated

45 enrolled 16 charts

Neoplasms